- Oops!Something went wrong.Please try again later.
Underwriters have an option to purchase up to $12 million of shares.
The company will use the proceeds to fund the clinical development of IDE397, preclinical and clinical development of other product candidates in its research pipeline targeting poly (ADP-ribose) glycohydrolase, and its share of costs under GSK collaboration and other general corporate purposes.
J.P. Morgan, Citigroup, Jefferies, and Guggenheim Securities are acting as joint book-running managers for the offering.
Recently, the company met the criteria to initiate an IDE397 tumor biopsy cohort arm of the dose-escalation study, with observed clinical pharmacodynamic (PD) modulation of plasma S-adenosyl methionine (SAM) satisfying the clinical protocol threshold of approximately 60% or higher.
Price Action: IDYA shares closed at $22.72 on Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.